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ABSTRACT
The CRISPR system provides adaptive immunity
against mobile genetic elements (MGE) in prokary-
otes. In type III CRISPR systems, an effector complex
programmed by CRISPR RNA detects invading RNA,
triggering a multi-layered defence that includes tar-
get RNA cleavage, licencing of an HD DNA nuclease
domain and synthesis of cyclic oligoadenylate (cOA)
molecules. cOA activates the Csx1/Csm6 family of
effectors, which degrade RNA non-specifically to en-
hance immunity. Type III systems are found in diverse
archaea and bacteria, including the human pathogen
Mycobacterium tuberculosis. Here, we report a com-
prehensive analysis of the in vitro and in vivo activi-
ties of the type III-A M. tuberculosis CRISPR system.
We demonstrate that immunity against MGE may be
achieved predominantly via a cyclic hexa-adenylate
(cA6) signalling pathway and the ribonuclease Csm6,
rather than through DNA cleavage by the HD domain.
Furthermore, we show for the first time that a type
III CRISPR system can be reprogrammed by replac-
ing the effector protein, which may be relevant for
maintenance of immunity in response to pressure
from viral anti-CRISPRs. These observations demon-
strate that M. tuberculosis has a fully-functioning
CRISPR interference system that generates a range
of cyclic and linear oligonucleotides of known and
unknown functions, potentiating fundamental and
applied studies.
INTRODUCTION
The CRISPR system provides adaptive immunity against
mobile genetic elements (MGE) in prokaryotes (reviewed
in (1,2)). CRISPR systems are classified into two major
classes and six major types: class 1 (types I, III and IV)
have multi-subunit effector complexes based around a Cas7
backbone subunit, whilst class 2 (types II, V and VI) are
single-subunit enzymes (3). The latter, encompassing Cas9,
Cas12 and Cas13, have shown great utility in genome en-
gineering applications due to their relative simplicity. How-
ever, class 1 systems are more widespread in prokaryotes.
Type III effector systems are arguably the most complex,
powerful and versatile of the characterized CRISPR in-
terference complexes. Assembled around a Cas7 backbone
that binds CRISPR RNA (crRNA) (4), they act as surveil-
lance complexes in the cell, detecting target RNAmolecules
from MGE via base-pairing to the crRNA. Target RNA
binding licenses the HD-nuclease domain of the Cas10 sub-
unit to degrade single-stranded DNA, providing a mech-
anism for co-transcriptional target DNA degradation (5–
10). In addition, the Cyclase/Palm domain of Cas10 is ac-
tivated for synthesis of cyclic oligoadenylate (cOA) (11–13).
cOA, which is assembled from 3–6 AMPmonomers to gen-
erate species from cA3 to cA6, is a potent second messen-
ger that in turn binds to downstream effector complexes
via a CRISPR Associated Rossman Fold (CARF) domain
(14). Diverse proteins with CARF domains have been iden-
tified computationally, but only one family has been stud-
ied extensively: the Csx1/Csm6 family that utilizes a C-
terminal HEPN (Higher Eukaryotes and Prokaryotes, Nu-
cleotide binding) domain to cleave RNA (15,16). These en-
zymes are important for CRISPR-based immunity in vivo
(17–19).Thus, type III CRISPR systems are capable of di-
recting a multi-faceted antiviral defence on detection of for-
eign RNA in the cell (Figure 1A).
Mycobacterium tuberculosis (Mtb) is the causative agent
of tuberculosis (TB), which imposes a huge burden on hu-
man health and on developing economies, with 10 million
new infections and 1.6million deaths in 2017 (WHOGlobal
Tuberculosis Report, 2018). The majority of Mtb strains
encode a complete CRISPR system (20), and indeed the
type III-A (or Csm) CRISPR system was originally labelled
as the ‘Mtube’ subtype based on the genes present in Mtb
strain H37Rv (21). CRISPR loci vary betweenMtb strains
and have been used formany years as a strain typing (spolig-
otyping) tool (22), suggesting uptake of DNA derived from
mycobacteriophage or other MGE by the CRISPR system
occurs. The type III-A system encoded byMtbH37Rv com-
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Figure 1. TheCRISPR system ofMycobacterium tuberculosis. (A) The CRISPR locus ofM. tuberculosis includes genes encodingCas6 (crRNAprocessing),
Csm1–5 (type III-A interference complex), Csm6 (ancillary ribonuclease), Cas1 and Cas2 (Adaptation). Cas6 cleaves the CRISPR RNA at the base of
a short hairpin to generate mature crRNA that is bound by the Csm complex. On target RNA binding, the Csm complex is expected to display three
enzymatic activities: target RNA cleavage by Cas7 (Csm3) (1), DNA cleavage by the HD domain (2) and cOA production by the cyclase domain (3). (B)
Purified, recombinant CRISPR-associated proteins ofM. tuberculosis. M: PageRuler Unstained (Thermo Scientific); 1: Csm1–5 interference complex; 2:
Csm1–5, Csm1 D630A, D631A (Cy variant); 3: Csm1–5, Csm3 D35A (C3 variant); 4: Csm6; 5: Cas6.
prises Csm1–6, with Cas6 for crRNA processing and the
adaptation proteins Cas1 and Cas2 next to the CRISPR ar-
ray (Figure 1A). In Mycobacterium bovis (BCG), the orga-
nization is identical with the exception of a truncating mu-
tation in the csm6 gene (20). Looking across the entirety of
the prokaryotic domains of life,Mtb is a rare example of an
isolated type III effector and associated adaptation system.
Little is known about the activity of the Mtb CRISPR
system, although recent work suggests it can provide mod-
est immunity against MGE (23). Here, we report the re-
constitution and characterization of the Mtb system both
in vitro and in vivo, in Escherichia coli. We demonstrate
that the Mtb Csm complex provides immunity via a cA6-
activated Csm6 ribonuclease, and that the system can be re-
programmed to provide cA4-modulated immunity by swap-
ping the cOA-activated effector protein.
MATERIALS AND METHODS
Cloning
Enzymes were purchased from Thermo Scientific, BioLine,
Promega or New England Biolabs and used according to
manufacturer’s instructions. Oligonucleotides (Supplemen-
tary Table S2) and synthetic genes (Supplementary Ta-
ble S3) were obtained from Integrated DNA Technolo-
gies (Coralville, IA, USA). Synthetic genes were codon-
optimized for E. coli and restriction sites for cloning incor-
porated. All constructs were verified by sequencing (GATC
Biotech, Eurofins Genomics, DE) unless stated otherwise.
Protein concentrations were determined by UV quantita-
tion (NanoDrop 2000, Thermo Scientific) using calculated
extinction coefficients (ExPASy, ProtParam software) un-
less stated otherwise.
CRISPR genes. All genes were obtained as synthetic
genes. To obtain N-terminal His6-fusion proteins, Mtb
cas10 (csm1), cas11 (csm2), cas7 (csm3), cas5 (csm4),
csm5 and csm6 were digested with NcoI and XhoI and
ligated into the corresponding sites of the expression vec-
tor pEHisTEV (24). The Mtb cas6 gene was cloned into
the NdeI and XhoI sites of the same vector to obtain the
C-terminal His6-fusion. We cloned a truncated version of
cas6, starting at Met53 relative to NCBI annotation, be-
cause the N-terminal region showed no homology to non-
mycobacterial Cas6 proteins, and a transcription start site
was identified within the predicted cas6 gene (25). Thioal-
kalivibrio sulfidiphilus csx1 was cloned into the NcoI and
BamHI sites of pEV5HisTEV to obtain a N-terminal His8-
fusion (13).
CRISPR arrays. A CRISPR array containing three Mtb
repeat sequences flanking two identical spacer sequences
targeting the pUC19 MCS was assembled by BamHI di-
gest of the double-stranded mtbCRISPR array oligonu-
cleotide (Supplementary Table S2) followed by ligation into
pCDFDuet™-1 (Novagen, Merck Millipore).Mtb cas6 was
cloned into MCS-2 to give pCRISPR.
A CRISPR array consisting of four identical spacers
targeting the tetracycline resistance gene, flanked by five
Mtb repeat sequences, was assembled from phosphorylated
oligonucleotides mtbCA Rep and mtbCA TetR-Sp (Sup-
plementary Table S2). The array was ligated into MCS-
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1 of pCDFDuet™-1 containing cas6 in MCS-2 to give
pCRISPR-Target.
Mtb Csm complex for in vitro studies. Cas10 (csm1),
csm2 and csm5 were cloned into pACYCDuet-1 (5′-NcoI,
3′-XhoI; Novagen, Merck Millipore), csm4 was cloned
into pEHisTEV (5′-NcoI, 3′-XhoI) and csm3 was inserted
into pEHisTEV (5′-NdeI, 3′-XhoI) by restriction enzyme
cloning. These constructs were used as templates for assem-
bly of M. tuberculosis CRISPR genes, including ribosome
binding sites, into MultiColi™ (Geneva Biotech, Gene`ve,
CH) acceptor and donor vectors by sequence- and ligation-
independent cloning (SLIC) as per manufacturer’s instruc-
tions. Briefly, His6-csm4, csm2 and cas10 were introduced
into the acceptor pACE; csm3, csm5were cloned into pDK;
Mca csm2 was inserted into pDC using restriction enzyme
cloning (5′-NdeI, 3′-XhoI). The acceptor and donor plas-
mids were then recombined using Cre recombinase to give
pCsm1–5. To obtain variant Csm complexes, His8-V5-csm4
(frompEHisV5TEV-Csm4),Mca csm2 (frompACYCDuet-
Mca Csm2) and cas10 (csm1) were introduced into pACE
by SLIC; and csm3, csm5 were inserted into the donor
plasmid pDK. Primer-directed mutagenesis was carried out
on the assembled acceptor and donor plasmids, before
Cre recombination to give pCsm1–5 C3 (Csm3 D35A) and
pCsm1–5 Cy (Csm1 D630A/D631A). The identity of all
donor and acceptor plasmids was verified by sequencing,
and the final, recombined construct was analysed by restric-
tion digest.
Mtb Csm complex for in vivo studies. The same templates
as for construction of pCsm1–5 C3 were used with the
addition of csm6 (pACYCDuet-1). The pACE assembly
was as for pCsm1–5 C3. Csm3, csm5 and csm6 were in-
troduced into pDK; for the Csm6 plasmid, the donor
plasmid en route to pCsm1–5 was used. Mutagenesis was
carried out as before. All constructs were verified by se-
quencing. Suitable acceptor and donor plasmid combina-
tions were then assembled by Cre recombination to give
pCsm1–6, pCsm1–5 Csm6, pCsm1–6 C3, pCsm1–6 Cy
and pCsm1–6 HD (Supplementary Table S1). The control
plasmid pCsm Control was obtained by Cre recombination
of pACE and pDKwithout inserts. The identity of the final,
recombined constructs was confirmed by restriction digest
analysis.
Construction of target plasmids. An arabinose-inducible
pRSFDuet™-1 (Novagen, Merck Millipore) derivative with
tetracycline resistance was constructed as follows. The araC
and pBAD region was polymerase chain reaction (PCR)-
amplified from pBADHisTEV (Huanting Liu, University
of St Andrews, UK) using primer pair ara-AvrII-R/F and
cloned into the XbaI and NdeI sites of pRSFDuet™-1 to
give pRSFara. The tetracycline resistance gene was PCR-
amplified from the MultiColi™ vector pACE2 using the
TetR primer pair; the pRSFara-backbone lacking its resis-
tance gene was PCR-amplified using primer pair RSFara.
The two PCRproducts were digested with SphI and BamHI
and joined through ligation to give pRAT.The pUC19MCS
/ lacZα gene was introduced into pRAT by megaprimer
PCR (primer pair lacZ-pRAT) to give pRAT-Target (Sup-
plementary Table S1).
Protein production and purification
Mtb Cas6. C-terminally His6-tagged Cas6 was expressed
in BL21 (DE3) grown in LB containing 50 g ml-1
kanamycin and 50 g ml−1 chloramphenicol. An overnight
culture was diluted 100-fold into fresh medium and grown
at 37◦C, 180 rpm to an OD600 of 0.4. The temperature
was lowered to 16◦C, and incubation continued until the
OD600 reached 0.8. Production was induced with 50 M
IPTG, and the cultures were continued for a further 20 h.
Cells were harvested by centrifugation. The pellet was re-
suspended in 50 mM Tris–HCl, 250 mMNaCl, 10 mM im-
idazole, 10% glycerol, pH 7.5, sonicated and the cell debris
removed by centrifugation. The cleared lysate was loaded
onto a pre-equilibratedHisTrapCrude FF (GEHealthcare)
column, washed with 50 mM Tris–HCl, 250 mM NaCl,
30 mM imidazole, 10% glycerol, pH 7.5 and eluted in a
gradient to 50 mM Tris, 250 mM NaCl, 500 mM imida-
zole, 10% glycerol, pH 7.5. Cas6-containing fractions were
pooled and further purified by gel filtration (HiLoad 16/60
Superdex pg 200, GE Healthcare) in 50 mM Tris–HCl, 250
mMNaCl, 10%glycerol, pH 7.5. Cas6 andCas6H47Nwere
concentrated as required using anAmiconUltra centrifugal
filter (MWCO 10 kDa, Merck-Millipore).
Mtb Csm complex. Escherichia coli C43(DE3) cells were
co-transformed with the MultiColi™ construct pCsm1–5
(or pCsm1–5 C3, pCsm1–5 Cy) and pCRISPR. Overnight
cultures were diluted 100-fold into LB containing 100 g
ml−1 ampicillin and 50 g ml−1 spectinomycin, incubated
at 37◦C, 180 rpm until the OD600 reached 0.8. After induc-
tion with 100 M IPTG, incubation was continued at 25◦C
for 5 h. Cells were harvested by centrifugation and pellets
stored at −20◦C. Cells were resuspended in lysis buffer (50
mMTris–HCl, 500 mMNaCl, 10 mM imidazole, 10% glyc-
erol, pH 7.5) and lysed by sonication. The cleared lysate
was loaded onto HisPur Ni-NTA resin (Thermo Scientific),
washed with lysis buffer and eluted with lysis buffer con-
taining 250 mM imidazole. Csm complex-containing frac-
tions were diluted 2-fold with lysis buffer to prevent aggre-
gation, pooled, then dialysed at 4◦C overnight in the pres-
ence of 0.3 mg ml−1 TEV protease against lysis buffer. The
protein solution was passed through His-Pur Ni-NTA resin
a second time, and the flow-through was concentrated using
an Amicon Ultracentrifugal filter (30 kDaMWCO,Merck-
Millipore) and further purified by gel filtration (HiPrep
16/60 Sephacryl pg 300 HR, GE Healthcare) using 20 mM
Tris–HCl, 250 mM NaCl, 10% glycerol, pH 7.5 as mobile
phase. When necessary, the Csm complex was further pu-
rified on MonoS 4.6/100 PE (GE Healthcare) in 20 mM
MES, 50mMNaCl, pH 6 and eluted using a salt gradient to
1 MNaCl. Single-use aliquots were flash-frozen and stored
at −80◦C.
Mtb Csm6 and T. sulfidiphilus Csx1. Mtb Csm6 and
TsuCsx1 were expressed in C43 cells. Cells were grown for
4 h at 25◦C before harvest by centrifugation at 4000 rpm at
4◦C for 15 min (JLA 8.1 rotor). Cells were lysed in buffer
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containing 50 mM Tris–HCl pH 8.0, 0.5 M NaCl, 10 mM
imidazole and 10% glycerol supplemented with 1 mg/ml
chicken egg lysozyme (Sigma-Aldrich) and one ethylenedi-
aminetetraacetic acid (EDTA)-free protease inhibitor tablet
(Roche) by sonicating six times for 1 min with 1 min rest
intervals on ice. Cell lysate was then ultracentrifugated at
40000 rpm (70 Ti rotor) at 4◦C for 45 min and loaded onto
a 5 ml HisTrap FF Crude column equilibrated with wash
buffer containing 50 mM Tris-HCl pH 8.0, 0.5 M NaCl,
30 mM imidazole and 10% glycerol. After washing un-
bound protein with 20 CV wash buffer, recombinant Csm6
or TsuCsx1 was eluted with a linear gradient of wash buffer
supplemented with 0.5 M imidazole across 16 CV, holding
at 10% for 2 CV, 20% for 4 CV and 50% for 3 CV. Csm6
could not be concentrated and was therefore further puri-
fied using MonoQ (GE Healthcare) anion exchange chro-
matography, diluting protein from nickel affinity fractions
directly in buffer containing 20 mM Tris-HCl pH 7.5 and
50 mMNaCl and eluting protein across a linear gradient of
buffer containing 20 mM Tris-HCl pH 7.5 and 1M NaCl.
For TsuCsx1, nickel affinity fractions containing the protein
were concentrated using a 10 kDa MWCO ultracentrifugal
concentrator, and further purified by size exclusion chro-
matography (S200 26/60;GEHealthcare) in buffer contain-
ing 20 mM Tris-HCl pH 8.0, 0.5 M NaCl and 1 mM DTT.
All proteins were aliquoted, flash frozen with liquid nitro-
gen, and stored at −80◦C.
Assays
Cyclic oligonucleotides. cA4 and cA6 were purchased from
BIOLOG Life Science Institute (Bremen, DE).
Oligonucleotides. All RNA and DNA oligonucleotides as
well as 6-FAM™-labelled RNA substrates were purchased
from Integrated DNA Technologies (Leuven, BE). For nu-
clease assays, labelled oligonucleotides were gel purified as
described previously (26). Duplexed DNA oligonucleotides
were prepared by mixing equimolar amounts of ssDNA
in 10 mM Tris-HCl, 50 mM NaCl, 0.5 mM EDTA, pH
8.0, heating to 95◦C for 10 min, followed by slow cooling.
Oligonucleotides were 5′-end-labelled with [ -32P]-ATP (10
mCi ml−1, 3000 Ci mmol−1; Perkin Elmer) using polynu-
cleotide kinase (Thermo Scientific). Oligonucleotides were
quantified spectophotometrically using calculated extinc-
tion coefficients (OligoAnalyzer tool, IDT). RNA ladders
were obtained by alkaline hydrolysis (Thermo Fisher Sci-
entific, RNA Protocols).
Cas6 ribonuclease assay. The reaction mixture contained
3 M Cas6 in 20 mM Tris–HCl, 100 mM potassium
glutamate, 1 mM DTT, 5 mM EDTA, 0.1 U l−1
SUPERase•In™ (Thermo Scientific), pH 7.5. Reactions
were initiated by addition of 5′ 6-FAM™-labelled mtbRe-
peat Cas6 RNA (Supplementary Table S2) to 50 nM final
concentration. The samples were incubated for up to 1 h at
37 ˚C. The reaction was stopped by extraction with phenol-
chloroform-isoamyl alcohol. RNA species were resolved on
a 20% denaturing (7 M urea) acrylamide gel in 1X TBE
buffer, and visualized by scanning (TyphoonFLA 7000, GE
Healthcare).
Target RNA cleavage by the Csm complex. The ribonucle-
ase activity of the Csm complex was assessed by adding 25
nM [5′-32P]-labelled target RNA (Supplementary Table S2)
to 0.8 MCsm, 5 mMMgCl2, 0.1 U l−1 SUPERase•In™
(Thermo Scientific), 50 mM Tris–HCl, 50 mM NaCl, pH
8.0, and incubating at 30◦C for up to 2 h. The reaction was
stopped by phenol–chloroform–isoamyl alcohol extraction
to remove proteins. P1.A26 RNA (Supplementary Table
S2) was used as non-target RNA control. Products were
separated by gel electrophoresis (20% denaturing polyacry-
lamide) and visualized by exposure to a BAS Storage Phos-
phor Screen (GE Healthcare).
DNase activity of the Csm complex. To test for DNase
activity of the Csm complex, 25 nM 5′-32P-labelled DNA
substrate was added to 0.8 M Csm, 200 nM target RNA,
0.1 mMCoCl2, 0.1 U l−1 SUPERase•In™ (Thermo Scien-
tific), 50 mMTris–HCl, 50 mMNaCl, pH 8.0. The solution
was incubated at 30◦C for 90 min, and the reaction stopped
by phenol–chloroform extraction. Products were analysed
as described above.
Cyclic oligoadenylate production and LC-MS analysis.
Cyclic oligoadenylate production was triggered by adding
2 M crude target RNA to 0.8 M Csm, 1 mM adeno-
sine triphosphate (ATP), 5 mM MgCl2, 0.1 U l−1
SUPERase•In™ (Thermo Scientific), 50 mM Tris–HCl, 50
mM NaCl, pH 8.0, and incubating at 30◦C for up to 2
h. The reaction was stoped by phenol–chloroform–isoamyl
alcohol extraction. Reaction mixtures that were used for
Csm6 or Tsu Csx1 activation assays were further extracted
with chloroform–isoamyl alcohol to remove residual phe-
nol. Liquid chromatography-high resolution mass spec-
trometry (LC-HRMS) analysis was performed on aThermo
Scientific Velos Pro instrument equipped with HESI source
and Dionex UltiMate 3000 chromatography system. Sam-
ples were desalted on C18 cartridges (Harvard Apparatus).
Compounds were separated on a Kinetex 2.6 m EVO C18
column (2.1× 5 mm, Phenomenex) using the following gra-
dient of acetonitrile (B) against 20 mM ammonium bicar-
bonate (A): 0–2 min 2% B, 2–10 min 2–8% B, 10–11 min 8–
95% B, 11–14 min 95% B, 14–15 min 95–2% B, 15–20 min
2%B at a flow rate of 350l min−1 and column temperature
of 40◦C. UV data were recorded at 254 nm. Mass data were
acquired on the FTmass analyser in positive ion mode with
scan range m/z 200–2000 at a resolution of 30 000.
Csm6 activation assay. Csm6 (125 nM dimer) was incu-
bated with 25 nM 5′-radiolabelled P1.A26 RNA substrate
together with 2 M cold RNA in 50 mM MES, 100 mM
potassium L-glutamate, pH 6.5. The reaction was started
by addition of synthetic cA6 or 0.1 volumes protein-free re-
action mixture from the cyclic oligoadenylate production
above. The reaction was stopped after 45 min at 37◦C by
phenol–chloroform extraction. Products were analysed by
20% denaturing polyacrylamide gel electrophoresis.
TsuCsx1 activation assay. Csx1 (500 nM dimer) was incu-
bated with 50 nM 5′-radiolabelled A1 RNA substrate and 1
McA4, 1 McA6 or 1 l Csm-derived cOA (see above) in
pH 7.5 buffer containing 20 mMTris–HCl pH 7.5, 150 mM
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NaCl and 1 mM DTT in a 10 l reaction volume at 35◦C.
Reactions were stopped at 1, 5, 15 or 30 min by the addition
of a reaction volume equivalent of phenol–chloroform and
extracted products were analysed by denaturing gel elec-
trophoresis as described above.
Plasmid immunity in vivo. pCsm1–6 and pCRISPR were
co-transformed intoE. coliC43(DE3). Plasmids weremain-
tained by selection with 100 g ml−1 ampicillin and 50 g
ml−1 spectinomycin. Competent cells were prepared by di-
luting an overnight culture 50-fold into fresh, selective LB
medium; the culture was incubated at 37◦C, 220 rpm un-
til the OD600 reached 0.8–1.0. Cells were collected by cen-
trifugation and the pellet resuspended in an equal volume of
60 mM CaCl2, 25 mM MES, pH 5.8, 5 mM MgCl2, 5 mM
MnCl2. Following incubation on ice for 1 h, cells were col-
lected and resuspended in 0.1 volumes of the same buffer
containing 10% glycerol. Aliquots (100 l) were stored at
−80◦C. Target or control plasmid (100 ng pRAT-Target,
100 ng pRAT, respectively) were added to the competent
cells, incubated on ice for 30 min and transformed by heat
shock. LB medium (0.5 ml) was added and the transforma-
tion mixture incubated with shaking for 2.5 h before col-
lecting the cells and resuspending in 100 l LB. A total of 5
l of a 10-fold serial dilution were applied in duplicate to
LB agar plates supplemented with 100 g ml−1 ampicillin
and 50 g ml−1 spectinomycin when selecting for recipients
only; transformants were selected on LB agar containing
100 g ml−1 ampicillin, 50 g ml−1 spectinomycin, 25 g
ml−1 tetracycline, 0.2% (w/v) -lactose and 0.2% (w/v) L-
arabinose. Arabinose was omitted when transcriptional in-
duction of target was not required. Plates were incubated
at 37◦C for 16–18 h. Colonies were counted manually and
corrected for dilution and volume to obtain colony-forming
units (cfu) ml−1, statistical analysis was performed with
RStudio (RStudio Inc., Boston, USA, version 1.2.1335).
The experiment was performed as two independent experi-
ments with two biological replicates and at least two tech-
nical replicates.
RESULTS
Production of the functional Mtb Csm complex
Although the Mtb type III-A effector complex was de-
scribed very early in the classification of CRISPR systems
(21), there have been no subsequent publications describ-
ing studies of the recombinant system. This is surprising
given the importance of Mtb as a human pathogen and
the relative lack of model type III CRISPR systems out-
with the hyperthermophiles. We took the initial approach
of expressing synthetic genes encoding Csm1–5 individu-
ally in E. coli using the expression vector pEhisV5Tev (27).
Most of the subunits were expressed strongly, but the Csm2
(Cas11) subunit was completely insoluble under all induc-
tion conditions tested.We also expressed theMtbCsm6 and
Cas6 enzymes in soluble form (Figure 1B). Cas6 was ob-
served to cleave a CRISPR RNA substrate to generate the
expected 8 nt 5′-handle (Supplementary Figure S1). This ac-
tivity was stimulated by the addition of a divalent cation, as
observed previously (23). However, the ability of Ca2+ to
support catalysis is suggestive of a role for the metal ion in
RNA folding and stability rather than a direct role in the
catalytic mechanism, and all other Cas6 enzymes studied
are metal-independent enzymes (reviewed in (28)).
We next constructed a plasmid to express all five subunits
of Mtb Csm simultaneously using the MultiColi™ system
(Geneva Biotech), along with a compatible pCDFDuet-1
derivative expressing an Mtb mini-CRISPR and the Cas6
enzyme (pCRISPR, Supplementary Table S1) to allow for
co-production of the crRNA-charged interference complex
inE. coli. Using a polyhistidine tag on the Csm4 (Cas5) sub-
unit, it was noted that all subunits except Csm2 could be
identified. Coupled with the observation that Csm2 was in-
soluble in isolation, we hypothesized that heterologous ex-
pression of this subunit was a barrier to successful expres-
sion of the Csm complex. We therefore added a gene en-
coding the Csm2 homologue from Mycobacterium canet-
tii (Mca) to the Csm expression vector (pCsm1–5, Sup-
plementary Table S1). The two proteins are 71% identi-
cal at the amino acid level. Gratifyingly, the Csm com-
plex could then be purified using affinity chromatography
followed by gel filtration (Figure 1B). Mass spectrometry
confirmed that all subunits were present. In all subsequent
Csm expression plasmids, theMtb csm2 gene was therefore
replaced by Mca csm2. Protein expression plasmids were
also constructed carrying site directed mutations targeted
to the active sites of the Csm complex: a Cyclase (Cy) vari-
ant (GGDD to GGAA, pCsm1–5 Cy) and a Csm3 D35A
variant (C3, pCsm1–5 C3, Supplementary Table S1), as de-
scribed in the methods. The variant interference complexes
were expressed and purified as described for the wild-type
(WT).
Target RNA and DNA cleavage byMtb Csm
The CRISPR array used in heterologous production of the
Csm effector complex contained two copies of the same ar-
tificial spacer to minimize heterogeneity. We first evaluated
the ability of Csm to cleave target RNA that was comple-
mentary to the crRNA. Incubation ofCsm effector complex
with 5′-radiolabelled target RNA (Figure 2 and Supplemen-
tary Figure S2) in the presence ofMg2+ resulted in five cleav-
age products (B1–B5) with the characteristic 6 nt spacing,
consistent with other type III effectors (29–32). This sug-
gests that 5 Cas7 subunits are present in the complex, al-
though we have not determined the subunit stoichiometry
definitively and it will likely vary with crRNA length. Non-
complementary RNA was not cleaved by the effector com-
plex (Supplementary Figure S2A); however, anti-tag RNA
with full-length complementarity to the crRNA (including
5′-handle), that mimics antisense RNA derived from the
CRISPR locus, produced the same cleavage pattern as ob-
served for target RNA (Supplementary Figure S2B). A vari-
ant Csm complex with a mutation targeted to the cyclase
domain (Cy) was indistinguishable from the WT protein
for RNA cleavage. However, a variant (C3) with the Csm3
(Cas7) D35A mutation was not competent for target RNA
cleavage, as expected (Figure 2) (30). We also investigated
DNA cleavage by the Mtb Csm effector complex. We ob-
served weak cleavage of ssDNA substrates by the WT com-
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Figure 2. Target RNA cleavage by the Csm complex. WT, Csm3 D35A
variant (C3) or cyclase variant (Cy) Csm were incubated with 5′-32P-target
RNA under single-turnover conditions for 0.5, 2, 5, 30, 90 min and anal-
ysed by denaturing PAGE. Five RNA cleavage sites (B1–B5) were ob-
served.
plex; however, a variant with a mutation in the HD nucle-
ase domain was still capable of degrading ssDNA, whilst
the Csm3D35A variant showed noDNase activity (Supple-
mentary Figure S3). No detectable hydrolysis was observed
forDNAbubbles or dsDNAand the observedDNase activ-
ity was not dependent on the presence of target RNA. To-
gether, these data suggest there is no functional HD nucle-
ase activity in the recombinant Mtb Csm complex in vitro.
Given that the complex is recombinant and chimeric, with
an orthologous Csm2 subunit, we cannot rule out the possi-
bility that the HD nuclease domain plays a more prominent
role in immunity in vivo inM. tuberculosis.
Cyclic oligoadenylate synthesis by the Csm complex
Most type III CRISPR systems are closely associated with
a gene encoding a Csm6 or Csx1 enzyme, which is activated
by cOA generated by the Cas10 cyclase domain on target
RNAbinding (11,12) and required for immunity (17,33,34).
To test for cOA production, we incubated the Csm inter-
ference complex with cold target RNA and ATP and anal-
ysed the products by LC-MS (Figure 3A). Mtb Csm pro-
duced cA3, cA4, cA5, cA6 in decreasing order of abundance.
The identity of cA4 and cA6 was further confirmed by com-
parison to synthetic standards (data not shown). We also
detected substantial amounts of the corresponding linear
OA triphosphates that are likely to be intermediates of cOA
biosynthesis. When the same analysis was performed on
metabolites produced by the Csm Csm3 D35A complex, a
significant shift in cOA profile towards larger ring sizes was
observed.
Activation ofM. tuberculosis Csm6 requires cA6
The cOA-dependent ribonucleases studied to date are acti-
vated by either cA6 or cA4 (11–13). To determinewhich cOA
species is required for activation ofMtbCsm6, we incubated
the recombinant protein with synthetic cA4 and cA6, along
with a radioactively labelled substrate RNA (Figure 3B).
cA4 at 50 nM did not activate the ribonuclease activity, but
in contrast cA6 showed strong activation at 5 nM and sup-
ported complete degradation of substrate RNA at 50 nM.
This confirms cA6 as the relevant activator ofMtbCsm6. To
investigate the activation of Csm6 by the Csm complex, we
set up an assay where RNA binding and cOA synthesis by
Csm are coupled to activation of Csm6 (13). In the presence
ofWTCsm and target RNA, strong activation of Csm6was
observed, consistent with the generation of cA6 by the Csm
complex. Non-target (NT) control DNA did not activate
Csm6, and neither did an RNA matching the 5′-handle of
the crRNA (anti-tag, AT). The variant Csm with a muta-
tion that inactivates the cyclase domain (Cy), as expected,
did not activate Csm6, whereas the variant deficient in tar-
get RNA cleavage (C3) was, as expected, proficient in Csm6
activation, confirming previous findings for a variety of type
III systems (11,13).
In vivo activity of the Csm complex
We next set out to test if the Csm complex was active in
vivo. A recent study of plasmid transformation in M. tu-
berculosis yielded 3- to 10-fold less transformants when the
introduced plasmid carried one of the spacer sequences of
the native CRISPR array, suggesting that theMtbCRISPR
system is functional in its native host (23). We tested the ca-
pability of Csm to confer immunity against incoming plas-
mids in the heterologous host E. coli. The genes for the
Csm interference complex were assembled together with
csm6 (pCsm1–6, Supplementary Table S1). pCsm1–6 was
co-transformed with pCRISPR, harbouring the CRISPR
array with cas6 and two identical spacers targeting the
pUC19 multiple cloning site (MCS) portion of the lacZ
gene. We constructed plasmid pRAT, which combines the
origin of replication of pRSF-Duet-1 (Novagen), compat-
ible with both Csm/CRISPR constructs, with tetracycline
resistance and an arabinose-inducibleMCS, and introduced
pUC19 lacZα, containing the target sequence, into pRAT
to give pRAT-Target. Plasmid maps are shown in Supple-
mentary Figure S4.
An E. coli C43 strain harbouring the completeMtb Csm
interference module, was transformed with 100 ng target
plasmid pRAT-Target or with pRAT as negative control.
Serial dilutions of the transformation mixture were applied
to plates with three different conditions (Figure 4A): select-
ing for pCsm1–6 and pCRISPR only, additionally selecting
for the incoming plasmid without induction of target ex-
pression, and finally selecting for the incoming plasmidwith
induction of target expression. The first condition provided
the number of recipient cells and served to establish that
differences in transformation efficiency were not due to dif-
ferent cell concentrations. The other two conditions were
designed to establish if target transcription was essential
for plasmid immunity. There was no significant difference
in number of recipients. The number of transformants on
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Figure 3. cOA production and Csm6 activation. (A) Extracted ion chromatograms of oligoadenylates produced by WT and Csm3 D35A variant (C3)
Csm complex. Identical y-scaling throughout. The identity of the cyclic OAs (cAn) and respective 5′-triphosphates (P3-An) is indicated by the number of
AMP subunits. Production of cOAs, cA5 and cA6 in particular, was significantly increased for the Csm3 D35A (C3) Csm complex. (B) Csm6 ribonuclease
activation by cyclic oligoadenylates.MtbCsm6 (125 nM) was incubated with 200 nM 5′-[32P]-substrate RNA at 37◦C for 30min in the presence of synthetic
oligoadenylates (cA4, cA6) or a 10-fold dilution of Csm-derived cOAs. CsmWT (800 nM), cyclase variant (Cy, 800 nM) or Csm3 D35A (C3, 200 nM) was
incubated with 1 mM ATP and 200 nM target (T), non-target (NT) or anti-tag (AT) RNA for 0.5, 2 (WT, C3), or 90 min (all others) at 30◦C. Only cA6
activated Csm6. For WT and C3 Csm, sufficient cA6 was produced within 0.5 min to switch on Csm6 ribonuclease activity; whereas no detectable amount
of cA6 was produced under all other conditions even after prolonged reaction time.
uninduced plates also showed no significance difference be-
tween the control and target plasmid. When target expres-
sion was induced, however,∼100 times fewer transformants
were observed for the target plasmid relative to control or
uninduced conditions (Figure 4A). This demonstrates that
the Csm-mediated immunity is functional in the heterolo-
gous host, and that immunity is dependent on target tran-
scription as observed in other type III systems (35).
Thus far, the observed plasmid immunity was less effi-
cient by one to three orders ofmagnitude compared to those
in other type III systems (5,19,33,35,36). To test whether
targeting a gene essential for plasmid maintenance would
provide a higher degree of immunity than when target-
ing a non-essential one as before, we constructed a new
CRISPR array with spacers targeting the tetracyline resis-
tance gene of pRAT. The new array together with Cas6 was
cloned into pCDFDuet-1 to give pCRISPR TetR and co-
transformed with the completeMtb Csm module (pCsm1–
6) into E. coli C43 as before. Constructs where csm6 had
been omitted (pCsm1–5 Csm6) or that carried inac-
tivating mutations in the Csm3 subunit (pCsm1–6 C3),
the cyclase (pCsm1–6 Cy) or the HD domain (pCsm1–
6 HD)were also constructed and introduced intoE. coli to-
gether with pCRISPR TetR. As a control, empty backbone
(pCsm Control) was co-transformed with pCDF-Duet-1.
Cells were transformed with pRAT, and a 10-fold serial
dilution was plated selecting for recipients (selection for
pCsm and pCRISPR TetR only) and for transformants
(additional selection for incoming plasmid and induction
of CRISPR-Cas genes).
We observed three orders of magnitude fewer transfor-
mants for the full WT Csm module (including Csm6) com-
pared to the empty vector control (Figure 4B). As expected,
the Csm3 active site variant (C3) was as active as WT Csm;
however, so was the Csm HD variant. No plasmid immu-
nity was observed for the Csm cyclase domain variant (Cy)
or when Csm6 was not present. This is strong indication
that cOA induced Csm6 ribonuclease activity is the driv-
ing force behind plasmid immunity for this system. It also
demonstrates that target RNA cleavage is not required for
immunity, nor is DNase activity, at least not in a heterolo-
gous host such as E. coli.
Reprogramming the Mtb Csm system as a cA4-mediated de-
fence
The observation that the Mtb Csm complex generates a
range of cOA species from cA3-cA6 is consistent with pre-
vious findings for type III systems (11–13). Thus, the cOA
species relevant for downstream immunity should be de-
fined by the CARF-family effector protein(s) present in the
organism. For Mtb, the native Csm6 enzyme is activated
by cA6. We sought to determine whether we could repro-
gramme the Mtb CRISPR system as a cA4-mediated de-
fence, by replacing Csm6 with an alternative effector pro-
tein. A candidate Csx1 protein from the gammaproteobac-
terium Thioalkalivibrio sulfidiphilus (37) was selected and
expressed inE. coli from a synthetic gene. The activity of the
purified recombinant protein (TsuCsx1)was tested against a
labelled RNA substrate in the absence and presence of cOA
species (Figure 5A). TsuCsx1 was strongly activated by syn-
thetic cA4 but not by cA6, demonstrating that this enzyme
is cA4 specific. Strong activation was also observed when
the enzyme was incubated with cOA generated by the Mtb
Csm complex, consistent with the observation that cA4 is a
significant component of this mixture (Figure 3A).
We proceeded to add the gene encoding TsuCsx1 to the
Mtb csm1–5 genes (pCsm1–5 Csx1). As before, E. coli C43
harbouring pCsm1–5 tsuCsx1 and pCRISPR, were trans-
formed with the target plasmid (pRAT-Target) and pRAT
as the control lacking the target sequence. The 10-fold se-
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Figure 4. Plasmid immunity assays ofMtb Csm in heterologous host Escherichia coli. (A) C43 harbouring pCsm1–6 and pCRISPR are transformed with
pRAT (control plasmid) or with pRAT-target (plasmidwith pUC19MCS target). Target transcriptionwas arabinose-inducible. In the absence of arabinose,
the transformation efficiency was independent of the presence or absence of target; whereas when target transcription was induced, a 2-log reduction of
transformation efficiency was observed for the target plasmid compared to the control plasmid. *** P-value (Welch two sample test, two tailed) < 1e-05;
significance threshold at< 0.05. (B) C43 harbouring pCsm1–6 or indicated mutants and pCRISPR TetR (target tetracycline resistance gene, constitutively
expressed) were transformed with pRAT. Vector control (Ctrl): backbone vectors without inserts; WT Csm, Csm1–5 only (Csm6, C6), Csm3 D35A (C3),
Csm1 (Cas10) D630A/D631A (cyclase mutant, Cy), Cas10 H18A/D19A (HD mutant, HD).
rial dilutions were applied to selective, inducing plates to
determine the number of transformants; the cell count for
recipients was carried out as before. We observed similar
levels of plasmid immunity for the cognate Mtb Csm6 and
the heterologous TsuCsx1 systems (Figure 5B), demonstrat-
ing that the downstream effector proteins determine which
cyclic oligoadenylate species is active for immunity, and that
the Csm interference complex is not specific for a given ri-
bonuclease or vice versa.
DISCUSSION
The type III-A (Csm) CRISPR system of M. tuberculosis
provides immunity via cOA signalling
M. tuberculosis harbours the archetypal type III-A
(‘Mtube’) CRISPR system, and the variability of CRISPR
loci in mycobacteria (spoligotyping) has been utilized to
classify isolates for over 20 years. Despite this, little has
been reported on the characterization of theMtb CRISPR
system, particularly in vitro. Initial work on reconstituting
the Mtb Csm complex in E. coli encountered problems
due to poor solubility of the Csm2 (Cas11) subunit. We
surmounted this hurdle by swapping the problematic
Mtb csm2 gene with that from the closely related species
Mycobacterium cannetti, allowing expression of Mtb Csm
complex that is functional both in vitro and in vivo. Such
an approach may find utility in other circumstances when
studying multi-protein complexes.
Having succeeded in constructing an active Mtb Csm
complex, we could dissect the contributions of the various
enzymatic activities of this complex to CRISPR-based im-
munity. We could detect no strong evidence for target RNA
dependent DNA cleavage by the HD nuclease domain of
theMtbCsm complex (Supplementary Figure S3). Further-
more, targeted mutation of the HD nuclease active site did
not affect the ability of the Mtb CRISPR system to pro-
vide immunity against plasmid transformation in E. coli,
and immunity was lost when the Cyclase active site was in-
activated and the HD nuclease unaffected (Figure 4). Tar-
get RNA dependent DNA cleavage by the HD nuclease do-
main of Cas10 has been demonstrated in vitro for the type
III-A complexes of Staphylococcus epidermidis (38), Strep-
tococcus thermophilus (7) and Thermus thermophilus (39),
and type III-B complexes of Thermatoga maritima (6), Py-
rococcus furiosus (5) and Sulfolobus islandicus (9). On the
other hand, not all type III CRISPR effectors support ro-
bust DNase activity in vitro (32), and not all type III sys-
tems have an intact HD nuclease domain (3). HD nuclease
activity is often not required for plasmid immunity in vivo,
although the cyclase activity of Cas10 and the presence of
a cOA effector nuclease clearly is (9,17–19). Recent analysis
of plasmid clearance by the type III-A system of S. epider-
midis revealed that highly transcribed plasmid targets were
cleared efficiently by DNA targeting, whilst low levels of
transcription resulted in a requirement for RNA cleavage
by the Csm6 nuclease. This suggests that these two aspects
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/17/9259/5545015/ by U
niversity of St Andrew
s Library user on 08 O
ctober 2019
Nucleic Acids Research, 2019, Vol. 47, No. 17 9267
A
B
Figure 5. Re-programming the Mtb Csm system for cA4-responsive immunity. (A) In vitro activity of TsuCsx1. The reaction contained 0.5 M TsuCsx1
dimer, 100 nM 5′-32P-labelled RNA A1, 20 mM Tris, 150 mMNaCl, 1 mM DTT, pH 7.5 and was conducted at 35◦C for 1, 5, 15, 30 min. Activators were
added as indicated; Csm-derived cOAs were from a 2 h reaction, otherwise as described for Figure 3. TsuCsx1 was activated by cA4 but not cA6, and
Csm-derived cOAs are able to induce Csx1 ribonuclease activity in vitro. (B) Plasmid immunity assay using pUC19 lacZα-targeting Csm effector complex
in Escherichia coli C43 (pCsm1–5 Csm6/tsuCsx1 and pCRISPR, Supplementary Figure S4). The ribonuclease was either the cognate Csm6 or TsuCsx1.
Cells were transformedwith pRAT (control plasmid) or pRAT-Target (target plasmid) and 10-fold serial dilutions were plated on selective plates containing
arabinose for induction of target transcription. TsuCsx1 confers the same level of plasmid immunity as the cognateMtb Csm6.
of type III defence systems can work in tandem, and assume
differing importance for immunity, depending on the biol-
ogy of the invading genetic element (36). Although we see
no target-activated role for the HD nuclease domain ofMtb
Csm, either in vitro or in E. coli, we cannot rule out a role in
vivo in the homologous host. It is possible that the recombi-
nant system generated here has resulted in deactivation of
the HD nuclease, for example, or that a missing component
is crucial for full function inM. tuberculosis.
Cyclic oligoadenylate synthesis has been studied for a va-
riety of type III CRISPR systems. One emerging paradigm
is that a range of cOA molecules, from cA3 to cA6, are
synthesized––at least for recombinant systems in vitro. We
observed a predominance of the smaller species forWTMtb
Csm (Figure 3A), consistent with observations for the type
III-A complex fromS. thermophilus (11).Notably, when tar-
get RNA cleavage was abolished by introduction of a D35A
mutation in the Csm3 subunit, the levels and distribution of
cOA species changed dramatically. A significant increase in
the amounts of the larger cA6 and cA5 species was observed,
with cA6 coming to predominate. This reflects the finding
that target RNA cleavage by the Csm3 subunit is the event
that deactivates the cyclase domain (13,40). However, even
with target RNA cleavage abolished, a range of cOA species
are synthesized. This leads to the question: is this a feature
or a bug? Or in other words, has the ability to generate a
range of cOA species been selected for by evolution, or just
not selected against?
Ancillary defence enzymes are replaceable parts for Type III
CRISPR systems
A number of Csx1/Csm6 family proteins have now been
studied structurally and/or biochemically (Table 1). As al-
ready noted, proteins in this family have an N-terminal
CARFdomain and aC-terminalHEPNdomain. They tend
to be named as ‘Csm6’ proteins if their genes are closely as-
sociated with those encoding a type III-A/Csm CRISPR
effector complex, and Csx1 proteins if they are not, but it is
not clear that this division relates to any intrinsic property
or sequence of family members. The enzymes from the Ar-
chaeal, Deinococcus-Thermus and Proteobacterial phlya
that have been studied to date all utilize cA4 as an activa-
tor (Table 1), with examples of cA6-dependent enzymes only
characterized so far in the Firmicutes and Actinobacteria.
As cA4 and cA6 have quite significantly different structures
and sizes, this is likely to be reflected in the structures of the
corresponding CARF domains that bind these ligands. To
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Table 1. Comparison of characterized Csx1/Csm6 family proteins
Species Phylum Gene CRISPR subtype PDB
cOA
activator Reference
S. solfataricus Crenarchaeota Sso1389 III-D 2I71 cA4 (13)
S. islandicus Crenarchaeota SiRe 0884 III-B cA4 (49)
P. furiosus Euryarchaeota PF1127 III-B 4EOG ?* (50)
M. thermautotrophicus Euryarchaeota MTH1076 III-A cA4 (32)
T. thermophilus Deinococcus-Thermus TTHB152 III-A 5FSH cA4 (12)
T. thermophilus Deinococcus-Thermus TTHB144 III-A cA4 (48)
T. sulfidiphilus Proteobacteria Tgr7 1803 III-B cA4 This work
S. thermophilus Firmicutes StCsm6 III-A cA6 (11)
E. italicus Firmicutes EiCsm6 III-A cA6 (23)
M. tuberculosis Actinobacteria Rv2818c III-A cA6 This work
*Activator has not been determined for PF1127, but predicted to be cA4.
date however, there is no structural information available
for any cA6-binding CARF domain––this is a priority for
future studies.
Based on the data collated in Table 1, it is already ap-
parent that the cOA activator utilized by any particular
type III system does not correlate with the CRISPR sub-
type. Although only type III-A systems are known to uti-
lize cA6, there are well-studied examples (such as T. ther-
mophilus andMethanothermobacter thermautotrophicus) of
type III-A systems with ancillary ribonucleases activated by
cA4. All type III systems studied to date have the capability
of making a range of cyclic oligoadenylates from cA3-cA6
(11–13,40). As we have shown here, the immunity provided
by a type III system can be readily converted from a cA6 to
a cA4-based mechanism, simply by replacing the ancillary
enzyme. This suggests there is no direct cross-talk between
the type III complex and the ribonuclease, other than via
the cOA activator. Given the extent of gene loss and gain
in CRISPR loci, the capture of a new CARF-family effec-
tor protein might be sufficient to potentiate a switch from
one cOA signalling molecule to another. It is equally possi-
ble that distinct effector proteins, activated by cA4 and cA6,
could operate in parallel in a single host species. This could
provide enhanced levels of immunity by supporting multi-
ple ancillary defence proteins, many of which remain un-
characterized so far. Furthermore, the ability to switch be-
tween reliance on cA4 or cA6 could be an effective mecha-
nism to maintain immunity in response to (putative) viral
anti-CRISPRs which disrupt the cOA signalling pathway.
Cyclic and linear oligoadenylate signalling––more to dis-
cover?
Another pressing question for type III CRISPR systems
concerns the role (if any) for cA3 molecules, which are of-
ten the most abundant species synthesized, at least in vitro
(11,12). Given the lack of 2-fold symmetry for cA3, recogni-
tion of this molecule may be accomplished by a sensing do-
main quite distinct from the dimeric CARF domain found
in many CRISPR-associated proteins (13). Recent discov-
eries of novel cyclic trinucleotides synthesiszed by bacterial
cGAS-like enzymes and detected by vertebrate innate im-
mune surveillance proteins (41,42) make this question per-
tinent. This is particularly true for organisms such asM. tu-
berculosis, which has an intracellular lifestyle in vertebrate
hosts with which it participates in a two-way communica-
tion via cyclic nucleotides (43,44). Furthermore, the signif-
icant quantities of nanoRNAs (eg A3-triphosphate) syn-
thesized by the Csm complex should not be discounted as
dead-end side products. NanoRNAs have been shown ca-
pable of priming transcription initiation in bacteria (45).
Recently, the CnpB (Rv2837c) protein, which can degrade
nanoRNAs, controls the transcription of the csm genes
and CRISPR RNA inM. tuberculosis (46). Deletion of the
cnpB gene leads to massive transcriptional upregulation of
the csm genes, which is consistent with a model whereby
nanoRNAs generated by the Csm cyclase domain play a
role in sculpting the transcriptional response to phage infec-
tion in cells with a type III CRISPR system by activating de-
fence gene expression. Clearly, there are still many avenues
to explore.
Finally, there is the requirement to re-set the cell to a
ground-state when infection has been cleared, which proba-
bly requires degradation of the cOA generated during infec-
tion. Specialized ‘ring nucleases’ that degrade cA4 have been
identified in archaea (47), and recent work has shown that
Csm6 enzymes can also slowly degrade cA4 in their CARF
domain, acting as self-limiting ribonucleases (48). There is
no published evidence yet for cA6 degradation enzymes,
but the most obvious candidates are the CARF domains
of Csm6 family proteins. Alternatively, given the larger size
and increased flexibility of cA6 compared to cA4, the former
may be degraded effectively by promiscuous ribonucleases
in the cell.
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